Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Metastatic Uveal Melanoma Clinical Trial

Official title:

Chemoembolization of Uveal Melanoma Hepatic Metastases Using 300mg of BCNU Dissolved in Lipiodol® Followed by Gelfoam® Embolization

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04728633
• Other study ID #: 20P.1076
• Status: Recruiting
• Phase: Phase 2
• Start date: September 27, 2021
• Est. completion date: March 31, 2026

Study information

• Verified date: September 2023
• Source: Thomas Jefferson University
• Contact: Carin Gonsalves, MD
• Phone: 215-955-6385
• Email: Carin.Gonsalves[@]jefferson.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.

Description:

PRIMARY OBJECTIVE:

To determine the efficacy (clinical response) in terms of disease control rate (DCR) (complete response [CR] + partial response [PR] + stable disease [SD]) with chemoembolization of hepatic metastases with 300 mg of carmustine (BCNU) in ethiodized oil in metastatic uveal melanoma patients.

SECONDARY OBJECTIVES:

To investigate overall survival (OS) and progression-free survival (PFS) in uveal melanoma patients with hepatic metastases.

To assess the toxicity of the above treatment regimen.

OUTLINE:

Patients undergo transarterial chemoembolization (TACE) by receiving an infusion of carmustine dissolved in ethiodized oil and an injection of gelatin sponge. Treatment repeats once every 4 weeks (Q4W) for bilobar disease or once every 7 weeks (Q7W) for unilobar disease in the absence of disease progression or unacceptable toxicity or until maximum clinical benefit is obtained.

After completion of study treatment, patients are followed up at 30 days, and then every 2 months for up to 2 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: March 31, 2026
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed metastatic uveal melanoma in the liver

• Tumor burden < 75%. Patients must have at least one tumor measuring >= 10 mm in longest diameter by magnetic resonance imaging (MRI) or triphasic computed tomography (CT) (if MRI is not available or contraindicated)

• No prior transarterial catheter-directed therapies. Prior hepatic tumor ablation, hepatic radiation or liver resection will be permitted as long as growing measurable liver tumors exists. Prior systemic treatments are allowed as long as there are no outstanding toxicities greater than grade 1

• Willingness and ability to give informed consent

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• Serum creatinine =< 2.0 mg/dl

• Bilirubin =< 2.0 mg/ml. Exceptions will be made for patients with diagnosed Gilbert's Syndrome. In this instance, a bilirubin level =< 3.0 mg/ml will be allowed for this patients with this syndrome

• Albumin >= 3.0 g/dl

• No ascites

• Granulocyte count >= 1500/m^3

• Platelet count >= 150,000/m^3

Exclusion Criteria:

• Less than 18 years of age

• Previous liver-directed treatments including immunoembolization, chemoembolization, radioembolization, hepatic arterial perfusion, or drug-eluting beads

• Presence of life-limiting extrahepatic metastasis that requires systemic treatment within 3 months. However, radiation treatment of extrahepatic metastases such as bone, lymph nodes or subcutaneous metastases will be permitted while the patient is on study. Zometa or X-Geva to treat bone metastases will also be permitted. Immune check-point inhibitors while on study will NOT be permitted

• Portal vein occlusion, or inadequate collateral portal venous flow, as determined by MRI

• Known active viral or autoimmune hepatitis requiring treatments with serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) equal or greater than 5 times normal

• Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry

• Presence of any other medical conditions that imply a survival of less than six months

• Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding due to varices or main portal vein occlusion. Abnormal coagulation test must be corrected prior to the procedure

• History of life-threatening allergic reaction to iodinated contrast or BCNU despite pre-treatment with steroids

• Pregnant and/or breastfeeding women

• Presence of known untreated brain metastases. If patients have had previous treatment for brain metastasis, an MRI or CT of the brain must confirm the stabilization of the brain metastasis for more than 4 weeks

• Biliary obstruction, biliary stent, or prior biliary surgery including sphincterotomy but excluding cholecystectomy

Related Conditions & MeSH terms

• Melanoma
• Metastatic Malignant Neoplasm in the Liver
• Metastatic Uveal Melanoma
• Neoplasms
• Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
• Uveal Neoplasms

Intervention

Drug:
• Carmustine
Given via infusion
• Ethiodized Oil
Given via infusion

Procedure:
• Transarterial Chemoembolization
Undergo TACE

Other:
• Medical Device Usage and Evaluation
Given gelatin sponge via injection

Locations

Country	Name	City	State
United States	Sidney Kimmel Cancer Center at Thomas Jefferson Univeristy	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best response to treatment	Response to treatment	After the completion of cycle 2 of chemoembolization (1 cycle = 4 or 7 weeks)
Primary	Disease control rate (DCR) including complete response + partial response + stable disease	All estimates of rates (e.g., DCR) will be presented with corresponding confidence intervals. For DCR, the method of Atkinson and Brown will be used to allow for the two-stage design using the criteria adapted from the international criteria proposed by Response Evaluation Criteria in Solid Tumors 1.03.	Up to 2 year
Secondary	Time to progression	Will be estimated by the Kaplan-Meier method.	From the first chemoembolization to the time when progression of liver metastases is confirmed, assessed up to 2 years
Secondary	Overall survival	Will be estimated by the Kaplan-Meier method. Date and cause of death will be recorded. The cause of death will be categorized as either cancer-related or cancer unrelated.	From the first chemoembolization until death, assessed up to 2 years
Secondary	Incidence of adverse events	Safety will be assessed and the toxicity of the treatment will be monitored using the National Cancer Institute Common Toxicity Criteria version 5. All estimates of rates (e.g., toxicity) will be presented with corresponding confidence intervals.	Up to 30 days after the last day of study participation